相关实验视频

Updated: Jun 23, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.5K

[瘤透淋巴细胞 (TILs) 在三阴性乳腺癌中]

Sh R Abdullaeva1, T Yu Semiglazova1,2, A S Artemyeva1

  • 1N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia.

Arkhiv patologii
|June 17, 2024
PubMed
概括

在三阴性乳腺癌 (TNBC) 中,高水平的瘤透淋巴细胞 (TIL) 与更好的结果有关. 这种预后生物标志物在40%以上时,可显著改善TNBC患者无事件生存率.

关键词:
这就是TILs.新辅助疗法是一种新辅助疗法.在 pCR 中,pCR 值为 pCR.三重阴性乳腺癌是什么瘤透的淋巴细胞.

更多相关视频

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

1.9K
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.1K

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511